Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bapineuzumab long-term extension in ApoE4 noncarrier Alzheimer's disease participants
NL-OMON38012Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of bapineuzumab in Alzheimer's disease (AD), sponsored by Pfizer. Primary endpoint: Long-term safety and tolerability. Started Jul 2011; status: active, not recruiting.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON38012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38012.